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Abstract:
Simian virus 40 large T-antigen (SV40 LT-Ag) is a 708 amino acid nuclear phosphoprotein. Among many functions of LT-Ag is its
ability to perform as an ATPase-helicase, catalyzing the unwinding of viral genome during replication. The LT-Ag has been employed
in the studies of helicase structure and function, and has served as a model helicase for the screening of antiviral drugs that target viral
helicase. In this study, using in vitro enzyme assays and in silico computer modeling, we screened a batch of 18 fluoroquinolones to
assess their potential as antivirals by virtue of their inhibition of the LT-Ag helicase. We found all fluoroquinolones to be inhibitory to
the helicase activity of LT-Ag. In our docking analysis, most of these tested drugs showed similarity in their interactions with LT-Ag.
Our study shows the potential of fluoroquinolones as antiviral drugs and of SV40 LT-Ag as a model protein for screening drugs
against viral helicases.
Keywords: SV40 LT-Ag, Fluoroquinolones, Antiviral drugs
Background:
Simian virus 40 (SV40) is a small, non-enveloped DNA virus [1].
The virus’ genome comprises two sets of genes: late and early
expressed [2]. The late expressed genes encode structural proteins
necessary for viral assembly; these include three capsid proteins
VP1, VP2, VP3 and a maturation protein agnoprotein [2]. The
early expressed genes encode proteins required for viral
replication. This set includes the small and large T antigens (STAg and LT-Ag, respectively) [3]. The SV40 LT-Ag is a 708 amino
acid nuclear phosphoprotein, with multiple biochemical activities
[4]. The LT-Ag is able to transform many cell types; its
transforming ability is mainly dependent upon its interaction
with cellular factors including retinoblastoma and p53 tumor
suppressor proteins [3]. The LT-Ag also acts as a regulator of
viral and cellular gene expression, and as an initiator of viral
DNA replication [5, 6]. The LT-Ag binds to specific sites in the
region of SV40 replication origin and promotes the local
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unwinding of DNA. LT-Ag recruits cellular DNA replication
proteins to the site, which include Topoisomerase I, replication
protein A, and DNA polymerases, and thus promotes SV40 DNA
replication [7].
Among many functions of LT-Ag is also its ability to perform as
an ATPase-helicase, catalyzing the unwinding of viral genome
during replication, harvesting the energy required for this
process by means of ATP hydrolysis [6]. The SV40 LT-Ag is a
member of superfamily 3 of helicases, which consists of ring
forming helicases [7]. In addition to oncology research, LT-Ag
has been employed in the studies of helicase structure and
function. The LT-Ag has served as a model helicase also for the
screening of antiviral drugs that target viral helicases [8]. In our
previous study, LT-Ag was used as a model helicase to develop a
non-radioactive helicase assay [9]. For the current study, using in
vitro and in silico methods, we screened a batch of 18
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fluoroquinolones to assess their potential as antivirals by virtue
of their binding to, and inhibition of, the LT-Ag helicase.
Methodology:
Helicase Assay:
Purified SV40 LT-Ag was purchased from CHIMERx, USA. As
described previously [9], the helicase substrate was prepared by
mixing single strands of complimentary oligonucleotides in 1:1
ratio to a final concentration of 20 µM each, heated to 95°C for 5
min, and then allowed to anneal by gradual cooling to room
temperature for 1 hr. Typically, each helicase reaction contained
20µl 5x helicase buffer (200mM Tris pH-7.6, 25mM MgCl2, 20mM
DTT, 125mM KCl, 10% glycerol and 0.5µg/ulBSA), 1mM ATP,
10µM DNA oligo substrate, 1x SYBR Green I and 1.44µM purified
helicase, in a total volume of 100µl. The reaction was incubated at
37°C for 30 min and carried out in triplicates. Adding 4µl of 0.5M
EDTA stopped reaction. Fluorescence was measured using
Chameleon Fluorescence Reader 2 (Hidex, Finland), at
excitation/emission 492/535 nm. For calculating the helicase
activity, readings were corrected by subtracting the background
fluorescence of a SYBR Green-only blank reaction mixture from
the fluorescence of the sample. The enzyme activity was then
expressed as percentage of unwound substrate as follows:
Percentage of unwound substrate = [(y-x)/y]*100
Where x and y represent the fluorescence of reaction,
respectively, with and without any added helicase.
Enzyme Inhibition Assay:
Inhibition assays for helicase activity were performed as reported
previously [9, 10]. Eighteen fluoroquinolones, in concentrations
of 0.1, 1, 10 or 100 µM, were tested for their inhibition on LT-Ag
helicase activity. These tested fluoroquinolones were:
Levofloxacin, Ciprofloxacin, Ofloxacin, Balofloxacin, Fleroxacin,
Enoxacin,
8Hydroxquinolinol,
Pefloxacin,
Lomefloxacin,
Nalidixic acid, Enrofloxacin, Cinoxacin, Difloxacin, Flumiquine,
8Quinolinol, Sparfloxacin, Norfloxacin, and Moxifloxacin. The
results were expressed as percent inhibition observed in the
presence of the inhibitor, taking LT-Ag helicase activity as 100%
in the absence of any added inhibitor.
Docking Studies:
To analyze the interactions between LT-Ag and the selected
fluoroquinolones, crystal structure of SV40 LT-Ag (PDB ID:
1SVO)
was
obtained
from
Protein
Data
Bank
(http://www.rcsb.org), while the SDF files of the
fluoroquinolones were obtained from the Pubchem library of the
NCBI database (http://www.ncbi.nlm.nih.gov/pccompound).
The SDF files were subsequently converted to mol2 format by
using OpenBabel GUI [11]. The binding pocket for the drug was
predicted using Molegro Virtual Docker (MVD) software. To select
the helicase-binding site, coordinates of the binding sphere were
designated between Glu473 and Lys445, whereas the radius of
search sphere was kept at default setting, i.e., 10Å. To predict
protein-ligand interactions, Lead IT or FlexX version 2.0, software
was employed [12, 13]. The docking was performed using the
default parameters of the program, and the Single Interaction
Scan algorithm of Lead IT was used for this analysis. This
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software generates more than 100 docking poses and presents
them in ascending order with respect to docking energy. To
verify these results, the same analyses were also performed with
MVD software.
Results:
Inhibition of LT-Ag Helicase Activity by Fluoroquinolones:
The LT-Ag helicase activity was measured in the presence of 0.1,
1.0,10 and 100μM fluoroquinolone. Percent inhibition of LT-Ag
helicase activity by all 18 fluoroquinolones was observed to
follow almost a linear trend (Figure 1). At 100μM concentration,
all drugs except Enrofloxacin, Flumiquine, Sparfloxacin and
8Quinolinol, showed 60-90% inhibition of helicase activity.
Similarly, at 10μM concentration, all fluoroquinolones, except
Sparfloxacin and 8Quinolol, showed 40-80% inhibition of helicase
activity. With the exception of Balofloxacin, Ofloxacin,
8Hydroquinolol, and, Sparfloxacin, all fluoroquinolones showed
30%-60% inhibition of LT-Ag helicase activity at 1 μM (Figure 1).
Docking studies:
The model of SV40 LT-Ag (PDB ID: 1SVO) was docked
individually with each of the above-mentioned 18
fluoroquinolones. Each fluoroquinolone was docked deep into
the active site of LT-Ag helicase protein molecule. Coordinates of
the LT-Ag binding sphere were designated between Glu473 and
Lys445. Based on the lowest docking energy, 6 fluoroquinolones,
namely, Balofloxacin, Ofloxacin, Pefloxacin, Lomefloxacin,
Ciprofloxacin, and Levofloxacin, were selected for detailed
analyses of their interactions with LT-Ag (Table 1). Except for
Lomefloxacin and Ofloxacin, all six fluoroquinolones showed Hbond interactions with Gly445 and Glu473 in the binding pocket
of LT Ag (Table2 and Figure 2). Although it did not form H-bond
interactions, amino acid Leu440 was found in the binding pocket
of all fluoroquinolones except Lome- and O-floxacin (Figure 2).
Overall, therefore, the interactions made by Lomefloxacin and
Ofloxacin were somehow unique compared to other drugs (Table
2 and Figure 2). Based on the free energy values, the affinity of
the six drugs for LT-Ag was found to be in the following order:
Balofloxacin>Pefloxacin>Lomefloxacin>
Ciprofloxacin
>
Levofloxacin >Ofloxacin (Table 1). The same order was
recapitulated when the docking energy of these fluoroquinolones
were calculated using a different software, namely, Molegro
(Table 1). Overall, Molegro recapitulated the interactions between
fluoroquinolones and SV40 LT-Ag (data not shown).
Table 1: Docking energies of Fluoroquinolone-LT Ag complexes: Docking
energy scores (KJ/mol) werepredicted usingFlexXand Molegrosoftware.
The drugs are arranged in ascending order of the docking energy scores
of their complexes with SV40 LT-Ag. The energy scores predicted for each
drug-protein complex by the two softwares, although on different scales,
were in agreement with each other.
Ligand
Balofloxacin
Pefloxacin
Lomefloxacin
Ciprofloxacin
Levofloxacin
Ofloxacin

Docking Energy (KJ/mol)
FlexX
Molegro
-16.4
-73.4
-16.1
-68.2
-15.6
-65.7
-15.0
-61.4
-14.0
-60.9
-13.6
-59.0
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Table 2: LT-Ag amino acid residues interacting with Fluoroquinolones:
The table shows amino acid residues constituting the binding pocket of
LT-Ag. Amino acids shown in bold were found to make H-bond
interactions with fluoroquinolones, while the remaining amino acid
residues represent residues residing in the binding pocket.

Ligand
Balofloxacin
Pefloxacin
Lomefloxacin
Ciprofloxacin
Levofloxacin
Ofloxacin

Interacting Amino acid Residues
Glu473, Gly445, Lys446, Leu440 Ala447
Lys446, Gly445 Glu473, Leu440 Ala447
Glu460, Ala447, Lys446, Leu448 Val463
Gly445, Glu473, Leu440, Ala447, Lys446
Gly445, Glu473, Ala447, Leu440, Lys446
Glu460, Asn449, Glu473, Asp474

Figure1: LT-Ag helicase inhibition by fluoroquinolones: Bars represent percent inhibition of LT-Ag helicase activity treated with
0.01, 0.1 µM, 1.0 or 10µM of the fluoroquinolone. With few exceptions, most of the fluoroquinolones exhibited 30–70% inhibition of LTAg helicase activity at 1.0µM and 10µM concentration. Each bar represents mean of triplicates ± SEM.
binding
affinities
in
the
following
order:
Discussion:
Balofloxacin>Pefloxacin>Lomefloxacin>Ciprofloxacin>Levofloxa
In this study we have used SV40 LT-Ag as a model viral helicase
cin >Ofloxacin. Docking analysis identified certain amino acids in
and
have
explored
the
inhibitory
interactions
of
the LT-Ag active site, namely, Gly445, Glu473, and Leu440 that
fluoroquinoloneson with this enzyme using in vitro as well as in
were found to interact frequently with most of the six selected
silico approaches. We tested the activity of a panel of 18
fluoroquinolones. For this study, we employed the nonfluorquinolones using a helicase assay and found all of them to
radioactive assay that we have previously published [10]. In this
inhibit the helicase activity of LT-Ag. Docking of these
assay, 18 different fluoroquinolones were tested on LT Ag
fluoroquinolones on LT-Ag was also performed using in silico
helicase activity. All of the tested drugs showed inhibition of
methods. Based on the free energy values, 6 fluoroquinolones
helicase activity to some degree. Most fluoroquinolones showed
were found to interact most strongly with LT-Ag, with their
inhibition of 40%-80% at 10uM and 30%-60% at 1uM. In our
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previously reported study on HCV NS3 helicase, all
fluoroquinolones we tested showed inhibition of NS3 helicase
activity as well, with Ofloxacin, Fleroxacin, Enoxacin,
8Hydroxyquinolinol, Difloxacin, Flumiquine and 8Quinolinol

exhibiting 10-40% inhibition of HCV NS3 helicase at 0.1µM
concentration [11]. In another study, helicase activity of SV40 LTAg was inhibited by Levo-, Cipro-, Trovo-, and O-floxacin [8].
The current results are therefore consistent with previous reports.

Figure 2: Docked conformation of Fluoroquinolones in the binding cavity of LT-Ag: Docked models in 2D format, generated by
FlexX, showing the binding pocket of LT-Ag with docked conformations of (A) Balofloxacin, (B) Pefloxacin, (C) Lomefloxacin, (D)
Ciprofloxacin, (E) Levofloxacin, and (F) Ofloxacin. Broken lines indicate H bonding.
observed on HCV NS3 and SV40 LT-Ag. Since the architecture of
Although all fluoroquinolones were found inhibitory to both the
the helicase active site represents diversification among different
viral helicases, as expected, the individual fluoroquinolones
viral helicases, the nature of their interaction with
behaved differently with respect to the level of inhibition
fluoroquinolones was expected to differ accordingly. A deeper
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understanding
of
the
differential
interaction
of
fluororoquinolones on different helicases may be obtained by
analyzing crystal structures of helicase-fluoroquinolone
complexes and/or by studying the effect of amino acid mutations
in the active site of LT-Ag. For the current study, we adopted an
in silico approach to further dissect the interactions of
fluoroquinolones at the LT-Ag active site.
Computer docking models of fluoroquinolone-LT-Ag helicase
also revealed certain key functional groups of fluoroquinolone
that were involved in their mutual interaction with LT-Ag
helicase. The docked models of fluoroquinolones and LT-Ag
showed that the piperazinyl moiety at position 7, carboxylic acid
at position 3 and oxoquinoline at position 4 in the
fluoroquinolone molecule were mostly involved in interaction
with the amino acid residues of LT-Ag. The docking output
reflected binding efficiency of LT-Ag and fluoroquinolones. The
binding affinity of Balofloxacin was the highest followed by
affinities
for
Pefloxacin,
Lomefloxacin,
Ciprofloxacin,
Levofloxacin, and Ofloxacin (-16.4, -16.1, -15.6, -15.0, -14.0, and 13.6, kJ/mol, respectively), as predicted by FlexX (Table 1). The
same trend was recapitulated when the docking of these drugs
was performed using Molegro. All of these fluoroquinolones also
showed 60-70% inhibition of helicase activity at 10µM
concentration in in vitro helicase assay (Figure 1). The molecular
interaction between Ofloxacin and SV40 LT-Ag was found to be
weakest as judged by docking energy scores (-13.6), which was
in agreement with in vitro assay results, where at 10µM
concentration it showed less than 60% inhibition of helicase
activity (Figure 1). It may be concluded, therefore, that the energy
scores roughly correlated with the performance of
fluoroquinolones in the invitro assays. On a deeper level,
discrepancies in a drug’s in situ and in vitro behavior may also be
attributed to the behavior of the drug in solution, and the effects
of environmental factors, such as pH and temperature.
Interestingly, Ofloxacin and Lomefloxacin showed interactions
that were unique from all the other fluoroquinolones we studied.
Since, structurally, Ofloxacin and Lomefloxacin are not
remarkably different from the rest of the drugs; it is possible that

the in situ spatial orientation of these two fluoroquinolones
differs from the other drugs we studied. This may be further
explored by deeper analysis of docked fluroquinolone-LT-Ag
complexes. It would be interesting to design in silico derivatives
of fluoroquinolones, combining features of Ofloxacin and
Lomefloxacin with other fluoroquinolones, and study their
docked complexes with LT-Ag and other helicases. This exercise
may provide fluroroquinolone derivatives that inhibit the
helicase activity more strongly than the existing drugs.
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